查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1835285

人類乳突病毒檢測市場（按檢測類型、技術、適應症和最終用戶分類）—2025-2032 年全球預測

Human Papillomavirus Testing Market by Test Type, Technology, Indication, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，人類乳突病毒檢測市場將成長 36 億美元，複合年成長率為 13.97%。

主要市場統計數據
基準年2024年 12.6億美元
預計2025年 14.4億美元
預測年份：2032年 36億美元
複合年成長率（%） 13.97%

策略性地實施臨床、技術和營運促進因素，重塑人類乳突病毒檢測和篩檢管道

在臨床證據、技術成熟度和醫療服務模式變革的推動下，人類乳突病毒檢測領域正在經歷持續變革時期。臨床醫生越來越重視高靈敏度的分子方法進行子宮頸癌篩檢，而公共衛生計畫則強調公平的可近性和簡化的病患管道。同時，照護現場設計和自我管理模式的創新正在降低檢測門檻，並在基層醫療和社區中創造新的接觸點。

因此，實驗室和設備開發商面臨新的壓力，需要將平台靈活性、通量和單次檢測成本的經濟性與不斷變化的支付方期望和診斷指南相協調。隨著趨勢的融合，整個生態系統的相關人員（製造商、臨床實驗室、醫療保健系統和政策制定者）​​必須協調短期營運需求和長期策略投資。在此背景下，定序診斷和數位PCR方法的興起提高了診斷準確性，但也需要在生物資訊學和監管策略方面進行協調一致的投資。

因此，決策者應將當前的轉變視為一個曲折點，而非一個短暫的周期。透過整合臨床證據、以使用者為中心的設計和彈性供應鏈實踐，組織可以定位其檢測解決方案，使其不僅能夠滿足當前的臨床需求，還能在不同的醫療環境中實現可擴展、永續的篩檢計畫。這種採用是構成本分析其餘部分的核心驅動力和約束框架，凸顯了技術、臨床管道和打入市場策略之間進行有意識協調的必要性。

深入分析技術成熟度、檢測分散化、數據整合和護理路徑調整，這些因素正在重塑整個醫療保健系統的 HPV 檢測服務

HPV檢測領域正沿著幾個相互依存的軸心發生變化，這些軸心共同構成了診斷和護理服務的重新定位。首先，隨著指南機構建議採用高靈敏度方法進行初步篩檢，分子檢測已成為當務之急。這種轉變推動了對基於PCR的平台和定序方法的需求，這些平台和方法可在不同類型的檢體中提供強大的分析效能。其次，從自採集試劑套件到近患者快速診斷，檢體篩檢和分散式檢查檢測方面的創新正在透過解決便利性、隱私性和可及性方面的障礙來擴大可及的患者群體。

第三，數位健康工具與實驗室資訊系統的整合，使得篩檢計畫更具凝聚力，其結果能夠推動及時的後續追蹤和護理協調。從孤立的檢測活動轉變為持續、可追蹤的篩檢流程，需要在互通性和資料管治進行投資，這為週轉時間和結果清晰度帶來了新的期望。第四，公共衛生重點正在從一次性篩檢轉向連接疫苗接種、篩檢和治療管道的全面預防策略。這種整合凸顯了能夠分層風險並為精準分流決策提供資訊的檢測的重要性。

最後，成本壓力和採購動態持續推動模組化平台的發展，以適應多種檢測需求和檢體類型。總而言之，這些轉變有利於靈活的技術、以患者為中心的採集方法，以及將診斷性能與可操作的醫療管道連接的生態系統。對於那些預見這些動態並採取靈活商業化和臨床整合計畫的相關人員來說，持續的轉型將為改善病患治療效果和差異化市場定位鋪平道路。

對 2025 年關稅變化如何改變整個診斷相關人員的供應鏈彈性、籌資策略和監管規劃進行實際評估。

諸如美國2025年實施的關稅調整等政策措施，對HPV檢測生態系統產生了複雜且累積的影響，其影響遠超簡單的成本調整。依賴全球供應鏈供應試劑、塑膠製品和儀器組件的製造商面臨投入成本和物流的直接壓力。為此，許多供應商加快了區域籌資策略，並鎖定了二級供應商，以保持生產的連續性。這些戰術性調整減少了對單一來源的依賴，但需要在驗證、品質監督和監管文件方面進行短期投資。

因此，實驗室和採購團隊透過長期合約、批量承諾和多年期服務協議尋求價值，同時應對某些進口耗材的標價上漲。此外，關稅引發了製造商和付款人之間關於單位定價永續性以及平衡成本和臨床影響的基本契約必要性的對話。重要的是，監管機構明確了診斷套件和定序試劑的分類和進口要求，迫使企業更新其合規藍圖並調整上市時間表。

從戰略角度來看，那些積極實現物流多元化、投資國內或近岸製造夥伴關係並重新設計包裝和運輸佈局的公司，在關稅環境下表現良好。然而，規模較小的診斷開發商和獨立實驗室由於談判籌碼有限且資本儲備薄弱，面臨不成比例的負擔。從中期來看，我們認為這些動態將重新調整供應商集中度，加速製造商之間的整合，並刺激創新，從而減少對受關稅影響的投入的依賴，同時保持分析性能和臨床效用。

詳細的細分分析揭示了測試類型、核心技術、臨床適應症和最終用戶偏好如何決定採用優先順序和操作要求

細分分析揭示了檢測類型、基礎技術、臨床適應症和最終用戶偏好如何影響產品設計、採用通路和營運優先順序。按類型分類的檢測包括細胞學方法（傳統塗片和液基細胞學）、基於PCR和定序的分子檢測，以及照護現場和自我管理用例的快速檢測方法。這些類別涵蓋了從基於形態學的篩檢到高靈敏度核酸檢測的頻譜，每個類別對檢體處理、操作人員技能和後續臨床可行性都有不同的要求。

支援檢測類型的技術細分凸顯了雜交捕獲方法與PCR和定序平台協同作用。對於PCR而言，數位PCR和即時PCR之間的差異會影響檢測極限、定量和通量的最佳化；而對於定序而言，差異在於擴展多重基因組解析度的下一代方法與可用於標靶確認和變異表徵的桑格法之間的差異。這些技術選擇會影響儀器佔地面積、工作流程自動化和生物資訊需求，實驗室在選擇系統時必須對此進行規劃。

細胞學和分子標記物聯合檢測方法涵蓋高風險族群和常規族群。主要篩檢管道依年齡層分層，區分適用於21-29歲年輕人及30歲以上族群的篩檢策略。每種適應症都有不同的敏感性-特異性權衡，並影響報銷談判。

最後，終端用戶細分概述了檢測的執行地點以及結果如何轉化為醫療服務。診所涵蓋基層醫療和專科診所，對設備規模、訓練和病患處理量均有限制。醫院包括私立和公立系統，其採購週期、認證要求和中心實驗室能力各不相同。實驗室本身也分為院內實驗室和獨立實驗室，這會影響規範經濟、發佈網路和投資期限。整合這些細分市場，使開發人員和買家能夠根據臨床工作流程的實際情況和付款人的期望，調整產品功能、定價和實施支援。

全面了解區域醫療保健系統成熟度、採購實務和基礎設施的差異如何影響全球市場 HPV 檢測的採用和實施

區域動態對偵測採用、供應鏈配置和監管管道有著顯著影響，在美洲、歐洲、中東和非洲以及亞太地區呈現不同的模式。在美洲，成熟的篩檢項目、先進的實驗室基礎設施以及不斷發展的支付模式有利於採用高靈敏度的分子檢測平台。因此，相關人員必須調整其篩檢策略，以因應集中式大容量偵測和分散式醫療點的需求。

在歐洲、中東和非洲，監管協調工作和區域採購機制影響著器械註冊和價格談判，這為製造商創造了複雜的環境，他們必須應對每個國家的衛生技術評估流程。該地區許多市場的公共預算有限，實驗室能力波動，這為低成本、可靠的分子檢測以及本地化生產和培訓的夥伴關係創造了機會。將計畫過渡到有組織的篩檢和整合疫苗宣傳活動通常需要衛生署和臨床網路之間的密切合作。

亞太地區市場成熟度參差不齊，從擁有先進實驗室網路的高度都市區，到注重可擴展且價格合理的檢測解決方案的新興市場，不一而足。私人醫療服務的快速成長，加上基因組學和定序基礎設施投資的不斷增加，正在推動高性能實驗室平台和創新照護現場診斷技術的普及。在所有地區，跨境供應鏈、臨床指南的協調以及數位化醫療賦能將決定檢測創新如何有效轉化為更完善的全民篩檢。

深入的競爭分析，展示平台提供者、試劑供應商、生物資訊公司和實驗室網路如何推動差異化價值和夥伴關係主導的市場進入

HPV檢測領域的競爭動態由許多知名診斷製造商、新興分子創新者、試劑和耗材供應商以及專業服務供應商共同塑造。大型平台供應商利用其已安裝的儀器和整合試劑模型來創造經常性收益，並透過互聯服務和數據分析擴展其提案。相較之下，快速分子分析和定序專家則憑藉標靶檢測、快速檢驗週期和以使用者為中心的設計脫穎而出，這些設計旨在滿足小眾臨床工作流程和服務不足地區的需求。

試劑供應商和試劑盒製造商發揮至關重要的作用，因為檢測性能和供應的連續性取決於可靠的耗材和經過驗證的供應鏈。同時，軟體和生物資訊供應商也變得越來越具有戰略意義，他們提供檢驗層，將原始分子數據轉化為臨床可操作的報告和工作流程自動化。獨立實驗室和聯網診斷服務供應商也在透過整合檢測量、最佳化參考工作流程以及協商反映通量效率的價格來發揮市場影響力。

設備原始設備製造商 (OEM) 與檢體採集創新者之間、臨床實驗室與付費方資助的篩檢之間以及診斷公司與區域分銷商之間的策略夥伴關係，對於市場滲透至關重要。此外，監管敏銳度和本地市場知識仍然是差異化因素。積極與醫療機構合作、投資臨床證據產生並支持實施訓練的公司，往往能夠加速採用。最終，這一切都取決於能否將強大的分析性能與切實可行的實施支援相結合，以應對不同醫療機構的物流現實。

為領導者提供切實可行的建議，以協調產品靈活性、分散測試、彈性供應鏈和證據生成，從而加速採用和影響

為了抓住HPV檢測領域的新機遇，產業領導者應採取多管齊下的策略，將技術藍圖、供應鏈彈性和臨床整合結合起來。首先，優先考慮支援多種檢測化學方法和檢體類型的平台靈活性，使客戶能夠整合工作流程並降低總體擁有成本。這種方法可以降低實驗室的採購複雜性，並在臨床網路中建立客戶黏著度。其次，透過檢驗自採集試劑套件和低複雜度的照護現場模式，投資分散式檢查模式，同時確保與後續通路和電子健康記錄的緊密整合。

第三，我們將透過供應商多元化、關鍵零件近岸外包以及建立庫存視覺化系統來預測中斷，從而增強供應鏈的韌性。第四，我們將推行將臨床結果數據與衛生經濟分析相結合的策略，以產生證據、支持報銷討論並向付款人展示價值。第五，我們將擴展實施服務，包括培訓、品質保證和互通性套件，以幫助買家快速做好營運準備並維持認證標準。最後，我們將與公共衛生機構、學術中心和商業實驗室建立策略夥伴關係，以促進指南的採用，並擴大最有利於服務不足人口的篩檢計畫。

透過實施這些建議，組織可以平衡短期營運績效和長期差異化，確保技術卓越轉化為可衡量的臨床影響和永續的商業模式。

對混合方法研究的透明描述，該研究結合了二次證據審查、專家訪談、監管分析和三角綜合來檢驗研究結果和建議。

調查方法結合了系統性證據整合、初步定性訪談以及監管和臨床指南的三角檢驗，從而獲得可靠的見解。二次研究涵蓋同儕審查文獻、公共衛生機構指南文件、臨床實務指南、器材監管文件和產業新聞稿，旨在建立技術能力、臨床管道和政策發展的全面基準。在適當情況下，臨床實驗室註冊庫和科學會議論文集提供了關於新型檢測方法性能和實施結果的同期證據。

我們的主要研究包括與各領域的專家進行結構化訪談，包括臨床實驗室技術人員、臨床醫生、採購負責人和監管專家，以了解他們對營運限制、應用促進因素和未滿足臨床需求的現實觀點。這些訪談幫助我們制定了技術採用路徑、供應鏈緊急措施和報銷動態的方案。我們對數據進行了三角測量，以確保我們的研究結果反映出多種觀點，並確保我們的建議既能解決技術可行性問題，又能切實解決實施問題。

我們的分析方法將專家意見的定性編碼與主題綜合相結合，以識別跨領域趨勢。我們的監管和政策分析考慮了分類途徑和報銷框架，以便在切合實際的市場准入時間表內製定商業策略。最後，我們清楚地記錄了調查方法的局限性，以幫助解讀：證據的可近性因地區和適應症而異，分子診斷領域的快速創新週期需要定期更新，以保持戰術性建議的相關性。

簡潔的結論強調需要在技術、供應鏈、臨床證據和實施方面進行策略合作，以實現改善 HPV 篩檢結果的承諾。

摘要：HPV檢測領域正處於曲折點，臨床重點、技術創新和營運現狀帶來了機遇，也帶來了複雜性。高靈敏度的分子檢測方法和定序能力提高了診斷的清晰度，而分散式、自主管理的檢測模式則擴大了服務匱乏人群的覆蓋範圍。同時，不斷變化的採購動態和近期的關稅相關壓力凸顯了供應鏈韌性和敏捷商業化策略的重要性。

整個生態系統相關人員的成功取決於產品設計與實際工作流程的契合度、對能夠證明臨床和經濟價值的證據進行投資，以及建立能夠促進可擴展應用的夥伴關係。隨著檢測技術的不斷發展，將卓越技術與培訓、互通性和品質保證等實用支援服務相結合的組織將最有能力影響篩檢計畫並改善患者預後。最後，我們強調，在技術開發、研發和營運執行過程中採取有意識的協作行動，對於將創新轉化為永續的公共衛生效益至關重要。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 居家 HPV檢體檢測的快速成長將提高服務匱乏女性的篩檢覆蓋率
  • 將人工智慧影像分析與 HPV DNA 檢測相結合，以提高診斷準確性和分類
  • 照護現場快速 HPV 檢測平台的進步，支援即時臨床決策
  • 擴大多重分子檢測，將 HPV 基因分型和其他性行為感染感染檢測結合在一次檢測中
  • 最新指南建議在國家計畫中優先進行 HPV篩檢而非細胞學篩檢
  • 加強診斷設備製造商和公共衛生機構在社區篩檢工作中的合作
  • 基於 CRISPR 的分子診斷技術能夠以低成本實現超靈敏、快速的 HPV 檢測
  • 人們對 DNA 甲基化等表觀遺傳生物標記的興趣日益濃厚，以改善 HPV 陽性患者的風險分層
  • 加大對低成本 HPV 檢測的開發投入，以彌補中低收入國家的篩檢差距
  • 遠端醫療HPV篩檢和追蹤服務擴大了遠距訪問和病人參與

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 人類乳突病毒檢測市場（依檢測類型）

  • 細胞學檢查
    • 傳統的
    • 液體基
  • 分子檢測
    • PCR相容
    • 序列已啟用
  • 快速檢測
    • 照護現場
    • 自我管理

9. 人類乳突病毒檢測市場（按技術）

  • 雜交捕獲
  • PCR
    • 數位的
    • 即時的
  • 順序
    • 新一代
    • 桑格

第 10 章。 人類乳突病毒檢測市場（按適應症）

  • 聯合檢查
    • 高風險
    • 常規
  • 初步篩檢
    • 21至29歲
    • 30歲或以上
  • 反射測試
    • Asc Us
    • Lsil

第 11 章。 人類乳突病毒檢測市場（按最終用戶）

  • 診所
    • 基層醫療
    • 專業
  • 醫院
    • 私人的
    • 公共
  • 實驗室
    • 醫院為基礎
    • 獨立

12. 人類乳突病毒檢測市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 人類乳突病毒檢測市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 人類乳突病毒檢測市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Seegene Inc.
    • GlaxoSmithKline PLC
    • Inovio Pharmaceuticals Inc.
    • Thermo Fisher Scientific Inc.
    • Johnson & Johnson
    • Merck Sharp & Dohme Corp.
    • Pfizer Inc.
    • Siemens Healthineers AG
    • Sanofi SA
    • AstraZeneca PLC
    • MedPath
Product Code: MRR-43127F7278E2

The Human Papillomavirus Testing Market is projected to grow by USD 3.60 billion at a CAGR of 13.97% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.26 billion
Estimated Year [2025] USD 1.44 billion
Forecast Year [2032] USD 3.60 billion
CAGR (%) 13.97%

A strategic introduction to the evolving clinical, technological, and operational drivers reshaping human papillomavirus testing and screening pathways

The landscape of human papillomavirus testing is undergoing a period of sustained transformation driven by clinical evidence, technological maturation, and shifting care delivery models. Clinicians increasingly prioritize high-sensitivity molecular approaches for cervical cancer screening while public health programs emphasize equitable access and streamlined patient pathways. At the same time, innovation in point-of-care designs and self-administered formats is lowering barriers to testing uptake and creating new touchpoints across primary care and community settings.

Consequently, laboratories and device developers face renewed pressure to align platform flexibility, throughput, and cost-per-test economics with evolving payer expectations and diagnostic guidelines. As trends converge, stakeholders across the ecosystem-manufacturers, clinical laboratories, healthcare systems, and policymakers-must reconcile short-term operational demands with longer-term strategic investments. In this context, the rise of sequencing-enabled diagnostics and digital PCR modalities augments diagnostic precision but also requires coordinated investments in bioinformatics and regulatory strategy.

As a result, decision-makers should view current shifts as an inflection point rather than a transient cycle. By integrating clinical evidence, user-centered design, and resilient supply chain practices, organizations can position testing solutions not only to meet present clinical needs but also to enable scalable, sustainable screening programs across diverse care settings. This introduction frames the core drivers and constraints that shape the remainder of the analysis, underscoring the need for deliberate alignment among technology, clinical pathways, and market access strategies.

A thorough analysis of technological maturation, decentralized testing, data integration, and care pathway alignment that is reshaping HPV testing delivery across healthcare systems

The HPV testing landscape is shifting along multiple, interdependent axes that together constitute a transformative reorientation of diagnostics and care delivery. First, molecular testing has stepped to the forefront as guideline authorities increasingly endorse high-sensitivity approaches for primary screening; this change has precipitated demand for PCR-based platforms and sequencing approaches that deliver robust analytic performance across diverse specimen types. Second, innovations in sample collection and decentralized testing-spanning self-sampling kits to near-patient rapid diagnostics-are expanding the pool of reachable patients by addressing convenience, privacy, and access barriers.

Third, the integration of digital health tools and laboratory information systems is enabling more cohesive screening programs where results drive timely follow-up and care coordination. Transitioning from siloed test events to continuous, trackable screening journeys requires investments in interoperability and data governance, and it introduces new expectations for turnaround times and result clarity. Fourth, public health priorities are shifting from episodic screening toward integrated prevention strategies that link vaccination, screening, and treatment pathways; such integration elevates the importance of tests that can stratify risk and inform precision triage decisions.

Finally, cost pressures and procurement dynamics continue to incentivize modular platforms that can serve multiple testing needs and specimen types. Taken together, these shifts favor flexible technologies, patient-centered collection methods, and ecosystems that couple diagnostic performance with actionable care pathways. For stakeholders that anticipate these dynamics and adopt adaptive commercialization and clinical integration plans, the ongoing transformation opens paths to both improved patient outcomes and differentiated market positioning.

A pragmatic assessment of how tariff policy shifts in 2025 have altered supply chain resilience, procurement strategies, and regulatory planning across diagnostic stakeholders

Policy measures such as tariff changes introduced in 2025 in the United States have imparted a complex, cumulative influence on the HPV testing ecosystem that extends beyond simple cost adjustments. Manufacturers that rely on global supply chains for reagents, plasticware, and instrumentation components experienced immediate pressure on input costs and logistics. In response, many suppliers accelerated regional sourcing strategies and qualified secondary suppliers to preserve production continuity. These tactical adjustments reduced single-source dependencies but required near-term investments in validation, quality oversight, and regulatory documentation.

Consequently, laboratories and procurement teams navigated higher list prices for certain imported consumables while simultaneously seeking value through longer-term contracts, volume commitments, and multi-year service agreements. In addition, the tariffs catalyzed conversations between manufacturers and payers about the sustainability of unit pricing and the need for outcome-based contracting that balances cost with clinical impact. Importantly, regulatory interactions compounded the operational picture as agencies clarified classification and import requirements for diagnostic kits and sequencing reagents, prompting firms to update compliance roadmaps and adjust market entry timetables.

From a strategic perspective, organizations that proactively diversified logistics, invested in domestic or near-shore manufacturing partnerships, and re-engineered packaging and transport footprints navigated the tariff environment more successfully. However, smaller diagnostic developers and independent laboratories faced disproportionate strain due to limited negotiating leverage and thinner capital reserves. In the medium term, these dynamics are likely to reshape supplier concentration, accelerate consolidation among manufacturers, and incentivize innovations that reduce reliance on tariff-exposed inputs while preserving analytical performance and clinical utility.

In-depth segmentation analysis revealing how test types, core technologies, clinical indications, and end user settings jointly determine adoption priorities and operational requirements

Segmentation analysis clarifies how choice of test type, underlying technology, clinical indication, and end-user setting shape product design, adoption pathways, and operational priorities. Tests categorized by type include cytology approaches-both conventional smears and liquid-based cytology-molecular assays that comprise PCR-enabled and sequencing-enabled modalities, and rapid formats that serve point-of-care and self-administered use cases. Together these categories reflect a spectrum from morphology-based screening to high-sensitivity nucleic acid detection, and each category imposes distinct requirements for specimen handling, operator skill, and downstream clinical actionability.

Underpinning test types, technology segmentation highlights the role of hybrid capture methods alongside PCR and sequencing platforms. Within PCR, differentiation between digital PCR and real-time PCR carries implications for limit-of-detection, quantitation, and throughput optimization, while sequencing divides into next-generation approaches that scale multiplexed genomic resolution and Sanger methods that retain utility for targeted confirmation and variant characterization. These technological choices affect instrument footprint, workflow automation, and bioinformatics needs that laboratories must plan for when selecting systems.

Clinical indication segmentation reveals divergent testing pathways: co-testing approaches that combine cytology and molecular markers encompass both high-risk and routine contexts; primary screening pathways are stratified by age cohorts, distinguishing younger adults aged 21 to 29 from screening strategies applied to those aged 30 and above; and reflex testing pathways address cytologic ambiguities such as atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesions, where reflex algorithms target specific triage thresholds. Each indication imposes different sensitivity and specificity trade-offs and shapes reimbursement conversations.

Finally, end-user segmentation outlines where tests are performed and how results flow into care. Clinics span primary care and specialist settings, imposing constraints on instrument size, training, and patient throughput. Hospitals include both private and public systems with differing procurement cycles, accreditation requirements, and central laboratory capabilities. Laboratories themselves differentiate into hospital-based and independent entities, with implications for economies of scale, referral networks, and investment horizons. Integrating these segmentation lenses enables developers and buyers to align product features, pricing, and implementation support with the realities of clinical workflows and payer expectations.

Comprehensive regional insight into how healthcare system maturity, procurement practices, and infrastructure variation shape HPV testing adoption and implementation across global markets

Regional dynamics exert a strong influence on testing adoption, supply chain configuration, and regulatory pathways, with distinct patterns observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established screening programs, a sophisticated laboratory infrastructure, and evolving payer models favor adoption of high-sensitivity molecular platforms, while at the same time disparities in access and rural coverage drive demand for self-collection and point-of-care solutions. Consequently, stakeholders must calibrate commercialization strategies to address both high-volume centralized laboratories and decentralized care venues.

Across Europe, Middle East & Africa, regulatory harmonization efforts and regional procurement mechanisms influence device registration and pricing negotiations, creating a complex environment for manufacturers that must navigate national health technology assessment processes. In many markets within this region, constrained public budgets and variable laboratory capacity create opportunities for lower-cost, robust molecular assays and for partnerships that localize manufacturing and training. Transitioning programs toward organized screening and integrating vaccination campaigns typically require close coordination between ministries of health and clinical networks.

In the Asia-Pacific region, heterogeneous market maturity spans advanced urban centers with cutting-edge laboratory networks to emerging markets prioritizing scalable, affordable testing solutions. Rapid growth in private healthcare delivery, combined with increasing investment in genomics and sequencing infrastructure, supports adoption of both high-throughput laboratory platforms and innovative point-of-care diagnostics. Across all regions, cross-border supply chains, clinical guideline harmonization, and digital health enablement will determine how effectively testing innovations translate into population-level screening improvements.

A detailed competitive analysis showing how platform providers, reagent suppliers, bioinformatics firms, and laboratory networks drive differentiated value and partnership-led market entry

Competitive dynamics within the HPV testing sector are shaped by a mix of established diagnostic manufacturers, emerging molecular innovators, reagent and consumable suppliers, and specialized service providers. Large platform providers leverage installed instrument bases and integrated reagent models to secure recurring revenue and to broaden their value proposition through connected services and data analytics. In contrast, nimble molecular and sequencing specialists differentiate with targeted assays, rapid validation cycles, and user-centric designs that address niche clinical workflows or underserved geographies.

Reagent suppliers and cartridge manufacturers play a crucial role because assay performance and supply continuity hinge on reliable consumables and validated supply chains. Parallel to this, software and bioinformatics vendors are becoming increasingly strategic, offering interpretive layers that translate raw molecular data into clinically actionable reports and workflow automation. Independent laboratories and networked diagnostic service providers also exert market influence by consolidating testing volumes, optimizing reference workflows, and negotiating pricing that reflects throughput efficiencies.

Strategic partnerships-between instrument OEMs and sample collection innovators, between clinical laboratories and payer-sponsored screening initiatives, and between diagnostics firms and regional distributors-are central to market penetration. Additionally, regulatory acumen and local market knowledge remain differentiators; firms that proactively engage with health authorities, invest in clinical evidence generation, and support implementation training often accelerate uptake. Ultimately, success hinges on the ability to combine robust analytical performance with practical implementation support that addresses the logistical realities of diverse care settings.

Actionable recommendations for leaders to align product flexibility, decentralized testing, resilient supply chains, and evidence generation to accelerate adoption and impact

Industry leaders should adopt a multi-pronged strategy that aligns technology roadmaps, supply chain resilience, and clinical integration to capture emerging opportunities in HPV testing. First, prioritize platform flexibility that supports multiple assay chemistries and specimen types so that customers can consolidate workflows and reduce total cost-of-ownership. This approach reduces procurement complexity for laboratories and creates stickiness across clinical networks. Second, invest in decentralized testing models by validating self-collection kits and low-complexity point-of-care formats while ensuring robust linkage to follow-up pathways and electronic health records.

Third, strengthen supply chain resilience through supplier diversification, near-shoring critical components, and building inventory visibility systems that anticipate disruptions. Fourth, pursue evidence-generation strategies that pair clinical outcomes data with health economic analyses to support reimbursement conversations and to demonstrate value to payers. Fifth, expand implementation services-training, quality assurance, and interoperability toolkits-that help buyers achieve rapid operational readiness and maintain accreditation standards. Finally, cultivate strategic partnerships with public health agencies, academic centers, and commercial laboratories to accelerate guideline adoption and to scale screening programs where underserved populations stand to benefit most.

By executing on these recommendations, organizations can balance near-term operational performance with longer-term differentiation, ensuring that technological excellence translates into measurable clinical impact and sustainable commercial models.

Transparent description of mixed-methods research combining secondary evidence review, expert interviews, regulatory analysis, and triangulated synthesis to validate findings and recommendations

The research methodology combines systematic evidence synthesis, primary qualitative interviews, and triangulation of regulatory and clinical guidance to produce robust insights. Secondary research encompassed peer-reviewed literature, public health agency guidance documents, clinical practice guidelines, device regulatory filings, and industry press releases to build a comprehensive baseline of technology capabilities, clinical pathways, and policy developments. Where appropriate, clinical trial registries and scientific conference proceedings provided contemporaneous evidence on emerging assay performance and implementation outcomes.

Primary research included structured interviews with subject matter experts spanning laboratorians, clinicians, procurement officers, and regulatory specialists to capture pragmatic perspectives on operational constraints, adoption drivers, and unmet clinical needs. These interviews informed scenario planning around technology adoption pathways, supply chain contingencies, and reimbursement dynamics. Data triangulation ensured that findings reflected multiple vantage points and that recommendations addressed both technical feasibility and implementation practicality.

Analytical approaches combined qualitative coding of expert input with thematic synthesis to identify cross-cutting trends. Regulatory and policy analyses reviewed classification pathways and reimbursement frameworks to situate commercial strategies within realistic market access timelines. Finally, methodological limitations were documented transparently to inform interpretation: evidence availability varies by region and indication, and rapid innovation cycles in molecular diagnostics require periodic updates to maintain the relevance of tactical recommendations.

A concise conclusion emphasizing the need for strategic alignment across technology, supply chains, clinical evidence, and implementation to realize the promise of improved HPV screening outcomes

In summary, the HPV testing landscape is at an inflection point where clinical priorities, technological innovation, and operational realities converge to create both opportunity and complexity. High-sensitivity molecular approaches and sequencing capabilities offer enhanced diagnostic clarity, while decentralized and self-administered testing formats expand reach to under-screened populations. At the same time, evolving procurement dynamics and recent tariff-related pressures underscore the importance of supply chain resilience and agile commercialization strategies.

For stakeholders across the ecosystem, success depends on aligning product design with real-world workflows, investing in evidence that demonstrates clinical and economic value, and building partnerships that facilitate scalable implementation. As testing technologies continue to evolve, organizations that couple technical excellence with pragmatic support services-training, interoperability, and quality assurance-will stand in the best position to influence screening programs and to improve patient outcomes. The concluding perspective emphasizes that deliberate, coordinated actions across technology development, market access, and operational execution are essential to translate innovation into sustainable public health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid growth in at-home self-sampling HPV testing to increase screening coverage among underserved women
  • 5.2. Integration of AI-driven image analysis with HPV DNA testing to enhance diagnostic accuracy and triage
  • 5.3. Advancements in point-of-care rapid HPV testing platforms for immediate clinical decision support
  • 5.4. Expansion of multiplex molecular assays combining HPV genotyping with other STI detection in a single test
  • 5.5. Implementation of guideline updates recommending primary HPV screening over cytology in national programs
  • 5.6. Rising collaboration between diagnostics manufacturers and public health agencies for community screening initiatives
  • 5.7. Emergence of CRISPR-based molecular diagnostics enabling ultra-sensitive rapid HPV detection at lower cost
  • 5.8. Growing focus on epigenetic biomarkers such as DNA methylation for improved risk stratification in HPV positive patients
  • 5.9. Increasing investment in low-cost HPV test development to address screening gaps in low- and middle-income countries
  • 5.10. Telehealth-enabled HPV screening and follow-up services expanding access and patient engagement in remote areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Human Papillomavirus Testing Market, by Test Type

  • 8.1. Cytology Tests
    • 8.1.1. Conventional
    • 8.1.2. Liquid Based
  • 8.2. Molecular Tests
    • 8.2.1. PCR Enabled
    • 8.2.2. Sequencing Enabled
  • 8.3. Rapid Tests
    • 8.3.1. Point Of Care
    • 8.3.2. Self Administered

9. Human Papillomavirus Testing Market, by Technology

  • 9.1. Hybrid Capture
  • 9.2. PCR
    • 9.2.1. Digital
    • 9.2.2. Real Time
  • 9.3. Sequencing
    • 9.3.1. Next Generation
    • 9.3.2. Sanger

10. Human Papillomavirus Testing Market, by Indication

  • 10.1. Co Testing
    • 10.1.1. High Risk
    • 10.1.2. Routine
  • 10.2. Primary Screening
    • 10.2.1. Age 21 To 29
    • 10.2.2. Age 30 And Above
  • 10.3. Reflex Testing
    • 10.3.1. Asc Us
    • 10.3.2. Lsil

11. Human Papillomavirus Testing Market, by End User

  • 11.1. Clinics
    • 11.1.1. Primary Care
    • 11.1.2. Specialist
  • 11.2. Hospitals
    • 11.2.1. Private
    • 11.2.2. Public
  • 11.3. Laboratories
    • 11.3.1. Hospital Based
    • 11.3.2. Independent

12. Human Papillomavirus Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Human Papillomavirus Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Human Papillomavirus Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Seegene Inc.
    • 15.3.2. GlaxoSmithKline PLC
    • 15.3.3. Inovio Pharmaceuticals Inc.
    • 15.3.4. Thermo Fisher Scientific Inc.
    • 15.3.5. Johnson & Johnson
    • 15.3.6. Merck Sharp & Dohme Corp.
    • 15.3.7. Pfizer Inc.
    • 15.3.8. Siemens Healthineers AG
    • 15.3.9. Sanofi S.A.
    • 15.3.10. AstraZeneca PLC
    • 15.3.11. MedPath

LIST OF FIGURES

  • FIGURE 1. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. HUMAN PAPILLOMAVIRUS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. HUMAN PAPILLOMAVIRUS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HUMAN PAPILLOMAVIRUS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CONVENTIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LIQUID BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR ENABLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING ENABLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SELF ADMINISTERED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY DIGITAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REAL TIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY NEXT GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SANGER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HIGH RISK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ROUTINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 21 TO 29, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY AGE 30 AND ABOVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY ASC US, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LSIL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SPECIALIST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITAL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 247. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 248. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 249. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 250. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 251. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 253. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 254. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 255. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 256. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 257. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 258. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 259. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 273. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2018-2024 (USD MILLION)
  • TABLE 278. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CYTOLOGY TESTS, 2025-2032 (USD MILLION)
  • TABLE 279. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2018-2024 (USD MILLION)
  • TABLE 280. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY MOLECULAR TESTS, 2025-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2018-2024 (USD MILLION)
  • TABLE 282. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY RAPID TESTS, 2025-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2018-2024 (USD MILLION)
  • TABLE 286. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PCR, 2025-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 288. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 290. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2018-2024 (USD MILLION)
  • TABLE 292. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CO TESTING, 2025-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2018-2024 (USD MILLION)
  • TABLE 294. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY PRIMARY SCREENING, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY REFLEX TESTING, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 305. LATIN AMERICA HUMAN PAPILLOMAVIRUS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. LATIN AMERICA